For the third quarter of the fiscal year ending December 2026, revenue was 883,793 thousand yen (Year-over-Year +12.5%), operating loss was 27,984 thousand yen, ordinary loss was 25,605 thousand yen, and net loss attributable to owners of parent for the quarter was 17,578 thousand yen. Full-year earnings guidance for 2026 has been revised and published: full-year revenue is 1,262 million yen, and the forecasted full-year net loss per share is 0.24 yen. The company will continue growth investments such as DX. Vaccine revenue has ended and is not recorded.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"5619","jir_company_name":"MRSO Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/5619-20261113-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending December 2026, revenue was 883,793 thousand yen (Year-over-Year +12.5%), operating loss was 27,984 thousand yen, ordinary loss was 25,605 thousand yen, and net loss attributable to owners of parent for the quarter was 17,578 thousand yen. Full-year earnings guidance for 2026 has been revised and published: full-year revenue is 1,262 million yen, and the forecasted full-year net loss per share is 0.24 yen. The company will continue growth investments such as DX. Vaccine revenue has ended and is not recorded.","jir_summary":"### Performance Overview\nRevenue in the third quarter increased year-over-year, with continued growth across bookings, advertising, and DX segments. Meanwhile, operating loss narrowed compared with the prior year due to increases in selling, general and administrative expenses. Vaccine revenue did not occur due to changes in municipal COVID-19 vaccination policies. The full-year earnings guidance for 2026 has been revised, and revenue is expected to grow year-over-year.\n\n### Outlook and Key Investment Considerations\nThe company positions DX promotion in the healthcare domain and expansion of preventive medicine as medium- to long-term missions, and plans to continue investments such as office expansion and workforce increases. While full-year forecasts assume revenue growth, net profit\/loss is expected to remain in the red. The key issue going forward is whether productivity improvement measures, including AI utilization, will improve cost-effectiveness.","jir_financial_highlights":"Revenue: 883,793 (YoY +12.5%)\nOperating loss: -27,984 (Previous year period -49,228)\nOrdinary loss: -25,605 (Previous year period -47,379)\nNet loss attributable to owners of parent (quarter): -17,578 (Previous year period -37,571)\nFull-year forecast Revenue: 1,262 (vs. previous forecast +17.1%)\nFull-year net income (per share): Unknown (Unknown)","jir_category":"","jir_hashtags":"#MRSOInc, #Earnings","jir_key_figures":"Revenue: 883,793 thousand yen (YoY +12.5%)\nOperating loss: -27,984 thousand yen\nOrdinary loss: -25,605 thousand yen","jir_meta_title":"MRSO Inc. Third Quarter Financial Summary for FY2026 - Highlights","jir_meta_description":"Key points from MRSO Inc.'s FY2026 third quarter financial summary: revenue grew year-over-year and operating loss narrowed. Summary of the revised full-year guidance and ongoing growth strategy.","jir_og_title":"MRSO Inc. Q3 Financial Summary Highlights","jir_og_description":"Summary of MRSO Inc.'s financial statement: revenue increased and losses narrowed. Focus on continued DX investments and growth strategy.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":60743,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-151342","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n